Top

Published in:

01-06-2023 | Ezetimibe | Review

Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review

Authors: Margaretha Klement, Heinz Drexel, Christoph H. Saely

Published in: Inflammopharmacology | Issue 4/2023

Abstract

Statins are the primary pharmacological intervention to reduce LDL cholesterol; they significantly reduce inflammatory markers. Ezetimibe also reduces LDL cholesterol and reduces cardiovascular events when given on top of statin therapy. Whether ezetimibe, like statins, reduces markers of inflammation is less clear. We, therefore, conducted a systematic literature research addressing the impact of ezetimibe on CRP, TNFα and IL-6 when given on top of statin therapy. Our work indicates that overall ezetimibe reduces inflammation on top of statin treatment. However, available data are limited for CRP and even more so for TNFα and IL-6.

Almquist T, Jacobson SH, Mobarrez F et al (2014) Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest 44:276–284. https://doi.org/10.1111/eci.12230CrossRefPubMed

Azar M, Valentin E, Badaoui G et al (2011) Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Am J Cardiol 107:1571–1574. https://doi.org/10.1016/j.amjcard.2011.01.038CrossRefPubMed

Ballantyne CM, Houri J, Notarbartolo A et al (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107:2409–2415. https://doi.org/10.1161/01.CIR.0000068312.21969.C8CrossRefPubMed

Ballantyne CM, Weiss R, Moccetti T et al (2007) Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 99:673–680. https://doi.org/10.1016/j.amjcard.2006.10.022CrossRefPubMed

Barbosa SP, Lins LC, Fonseca FA et al (2013) Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci 92:845–851. https://doi.org/10.1016/j.lfs.2013.02.018CrossRefPubMed

Bays HE, Ose L, Fraser N et al (2004) A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary. Clin Ther 26:1758–1773. https://doi.org/10.1016/j.clinthera.2004.11.016CrossRefPubMed

Berthold HK, Berneis K, Mantzoros CS et al (2013) Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J 47:20–27. https://doi.org/10.3109/14017431.2012.734635CrossRef

Bohula EA, Giugliano RP, Cannon CP et al (2015) Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation 132:1224–1233. https://doi.org/10.1161/CIRCULATIONAHA.115.018381CrossRefPubMed

Collins R, Armitage J, Parish S et al (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22. https://doi.org/10.1016/S0140-6736(02)09327-3CrossRef

Dawson JA, Choke E, Loftus IM et al (2011) A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 41:28–35. https://doi.org/10.1016/j.ejvs.2010.08.023CrossRefPubMed

Dolezelova E, Stein E, Derosa G et al (2017) Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. Br J Clin Pharmacol 83:1380–1396. https://doi.org/10.1111/bcp.13250CrossRefPubMedPubMedCentral

Feldman T, Davidson M, Shah A et al (2006) Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Clin Ther 28:849–859. https://doi.org/10.1016/j.clinthera.2006.06.001CrossRefPubMed

Ference BA, Ginsberg HN, Graham I et al (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 38:2459–2472. https://doi.org/10.1093/EURHEARTJ/EHX144CrossRefPubMedPubMedCentral

Habara M, Nasu K, Terashima M et al (2014) Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. Am J Cardiol 113:580–587. https://doi.org/10.1016/j.amjcard.2013.10.038CrossRefPubMed

Krysiak R, Zmuda W, Okopien B (2014) The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc Ther 32:40–46. https://doi.org/10.1111/1755-5922.12057CrossRefPubMed

Krysiak R, Okopień B (2011) The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmaco. https://doi.org/10.1097/FJC.0b013e318211703b

Lins LCA, França CN, Fonseca FAH et al (2014) Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys 70:687–696. https://doi.org/10.1007/s12013-014-9973-9CrossRefPubMed

Oh M, Kim H, Shin EW et al (2021) Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation. Medicine (baltimore) 100:e25114. https://doi.org/10.1097/MD.0000000000025114CrossRefPubMed

Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188. https://doi.org/10.1093/EURHEARTJ/EHZ455CrossRefPubMed

Marcus ME, Manne-Goehler J, Theilmann M et al (2022) Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Heal 10:e369–e379. https://doi.org/10.1016/S2214-109X(21)00551-9/ATTACHMENT/7B1276F1-8390-4F14-ABBC-DF73DC627832/MMC2.PDFCrossRef

Morrone D, Weintraub WS, Toth PP et al (2012) Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223:251–261. https://doi.org/10.1016/j.atherosclerosis.2012.02.016CrossRefPubMed

Newman CB, Tobert JA (2015) Statin intolerance: reconciling clinical trials and clinical experience. JAMA–J Am Med Assoc 313:1011–1012. https://doi.org/10.1001/jama.2015.1335CrossRef

Nicholls SJ, Ray KK, Ballantyne CM et al (2017) Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the accentuate trial. Atherosclerosis 261:12–18. https://doi.org/10.1016/j.atherosclerosis.2017.04.008CrossRefPubMed

Oh MS, Min YJ, Kwon JE et al (2011) Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients. Korean Circ J 41:253–258. https://doi.org/10.4070/kcj.2011.41.5.253CrossRefPubMedPubMedCentral

Padhy BM, Yadav R, Gupta YK (2013) Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Singapore Med J 54:90–95. https://doi.org/10.11622/smedj.2013031CrossRefPubMed

Pearson T, Ballantyne C, Sisk C et al (2007) Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 99:1706-1713.e1. https://doi.org/10.1016/j.amjcard.2007.01.062CrossRefPubMed

Prati F, Marco V, Paoletti G, Albertucci M (2020) Coronary inflammation: why searching, how to identify and treat it. Eur Hear J Suppl 22:E121–E124. https://doi.org/10.1093/EURHEARTJ/SUAA076CrossRef

Ren Y, Zhu H, Fan Z et al (2017) Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med 14:4942. https://doi.org/10.3892/ETM.2017.5175CrossRefPubMedPubMedCentral

Ridker PM, Cannon CP, Morrow D et al (2005) C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28. https://doi.org/10.1056/NEJMoa042378CrossRefPubMed

Ridker PM, Danielson E, Fonseca FAH et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646CrossRefPubMed

Sager PT, Melani L, Lipka L et al (2003) Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92:1414–1418. https://doi.org/10.1016/j.amjcard.2003.08.048CrossRefPubMed

Sager PT, Capece R, Lipka L et al (2005) Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179:361–367. https://doi.org/10.1016/j.atherosclerosis.2004.10.021CrossRefPubMed

Sahebkar A, Di Giosia P, Stamerra CA et al (2016) Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br J Clin Pharmacol 81:1175–1190. https://doi.org/10.1111/bcp.12905CrossRefPubMedPubMedCentral

Salgado MM, Manchado A, Nieto CT et al (2021) Synthesis and modeling of ezetimibe analogues. Molecules. https://doi.org/10.3390/molecules26113107CrossRefPubMedPubMedCentral

Samuel M, Tardif JC, Khairy P et al (2021) Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Hear J Qual Care Clin Outcomes 7:486. https://doi.org/10.1093/EHJQCCO/QCAA045CrossRef

Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301–1308. https://doi.org/10.1056/NEJM199511163332001CrossRefPubMed

Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3–11. https://doi.org/10.1016/j.phrs.2014.03.002CrossRefPubMed

Study P, Alvarez-sala LA, Cachofeiro V et al (2008) Effects of fluvastatin extended-release (80 mg ) alone and in combination with ezetimibe (10 mg ) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia : a 12-week. Lipids. https://doi.org/10.1016/j.clinthera.2008.01.013CrossRef

Undas A, MacHnik A, Potaczek DP et al (2011) Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 58:167–172. https://doi.org/10.1097/FJC.0b013e31821e8cb2CrossRefPubMed

Wang X, Zhao X, Li L et al (2016) Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease. Hear Lung Circ 25:459–465. https://doi.org/10.1016/j.hlc.2015.10.012CrossRef

Wang J, Ai XB, Wang F et al (2017) Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Int Angiol 36:467–473. https://doi.org/10.23736/S0392-9590.17.03818-4CrossRefPubMed

Yu E, Malik VS, Hu FB (2018) Cardiovascular disease prevention by diet modification: JACC health promotion series HHS public access. J Am Coll Cardiol 72:914–926. https://doi.org/10.1016/j.jacc.2018.02.085CrossRefPubMedPubMedCentral

Zhao TX, Kostapanol M, Griffiths C et al (2018) Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS). https://doi.org/10.1136/bmjopen-2018-022452

Title: Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review
Authors: Margaretha Klement
Heinz Drexel
Christoph H. Saely
Publication date: 01-06-2023
Publisher: Springer International Publishing
Keywords: Ezetimibe
Simvastatin
Statins
Fluvastatin
Atorvastatin
Rosuvastatin
Published in: Inflammopharmacology / Issue 4/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01209-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

Umbelliferon: a review of its pharmacology, toxicity and pharmacokinetics

Mito-TEMPO mitigates 5-fluorouracil-induced intestinal injury via attenuating mitochondrial oxidative stress, inflammation, and apoptosis: an in vivo study

Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4+ T cells in patients with primary Sjögren's syndrome

Kolaviron modulates angiogenesis, apoptosis and inflammatory signaling in rat model of testosterone propionate-induced benign prostate hyperplasia

Fractionated whole body γ-irradiation aggravates arthritic severity via boosting NLRP3 and RANKL expression in adjuvant-induced arthritis model: the mitigative potential of ebselen

Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach